Consensus Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Market Closed - Nasdaq 04:00:00 2024-02-20 pm EST 5-day change 1st Jan Change
23.5 USD +1.08% Intraday chart for Myriad Genetics, Inc. +10.28% +22.78%

Evolution of the average Target Price on Myriad Genetics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ff5.4osMcmA8cirwE9cKjygz5P4WVOThsM3YAiNvTId2vVE.qc5VQjd-G3XCX4Q72loGqJ9JGY-g57yRRUk_ftg50CKV4WdfOHkXWLljng~b2fb8c4bcfbe933a856e1ddd9582b6b0
Goldman Sachs Adjusts Myriad Genetics' Price Target to $31 From $28, Maintains Buy Rating MT
BofA Securities Adjusts Price Target on Myriad Genetics to $20 From $18, Maintains Underperform Rating MT
Wells Fargo Initiates Myriad Genetics at Equalweight Rating With $20 Price Target MT
Wolfe Research Initiates Myriad Genetics With Outperform Rating With $28 Price Target MT
BofA Securities Trims Price Target on Myriad Genetics to $18 From $21, Maintains Underperform Rating MT
JPMorgan Adjusts Myriad Genetics' Price Target to $17 From $18, Keeps Underweight Rating MT
Goldman Sachs Adjusts Price Target on Myriad Genetics to $28 From $25, Maintains Buy Rating MT
Goldman Sachs Upgrades Myriad Genetics to Buy From Sell, Raises Price Target to $25 From $18 MT
ANALYST RECOMMENDATIONS : Chevron, Deere & Co, Nvidia, Steel Dynamics... Our Logo
Jefferies Raises Myriad Genetics' Price Target to $22 From $19, Hold Rating Kept MT
Morningstar Downgrades Myriad Genetics to Sell From Hold, $18.50 Price Target MT
Goldman Sachs Cuts Myriad Genetics' Price Target to $18 From $20, Sell Rating Kept MT
Stephens Adjusts Price Target on Myriad Genetics to $24 From $17, Maintains Equal-Weight Rating MT
Raymond James Adjusts Price Target on Myriad Genetics to $27 From $25, Maintains Outperform Rating MT
Raymond James Upgrades Myriad Genetics to Outperform From Market Perform, Price Target is $25 MT
SVB Securities Adjusts Price Target on Myriad Genetics to $25 From $27, Maintains Market Perform Rating MT
Stephens Starts Myriad Genetics at Equalweight With $22 Price Target MT
MYRIAD GENETICS : Raymond James Initiates Coverage on Myriad Genetics With Market Perform Rating MT
MYRIAD GENETICS : Goldman Sachs Starts Myriad Genetics at Sell With $25 Price Target MT
MYRIAD GENETICS : JP Morgan Adjusts Price Target for Myriad Genetics to $20 From $12, Maintains Underweight Rating MT
MYRIAD GENETICS : SVB Leerink Adjusts Myriad Genetics' Price Target to $33 from $20, Keeps Market Perform Rating MT
Myriad Genetics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2017; Raises Earnings Guidance for the Full Year of 2018; Provides Earnings Guidance for the Third Quarter of 2018; Provides Tax Rate Guidance for the Fiscal Year 2019 CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
23.5 USD
Average target price
22.5 USD
Spread / Average Target
-4.26%
High Price Target
31 USD
Spread / Highest target
+31.91%
Low Price Target
14 USD
Spread / Lowest Target
-40.43%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Myriad Genetics, Inc.

BofA Securities
Goldman Sachs
Wells Fargo Securities
Wolfe Research
JPMorgan Chase
Morningstar
Jefferies & Co.
Stephens Inc.
Raymond James
SVB Securities LLC
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer